view pamphlet

TOF2015Thoracic Oncology Forum

9-11 April 2015 | Crowne Plaza Hotel, Jeddah, Saudi Arabia

The 3rd Annual Scientific Conference of The Saudi Lung Cancer Association (SLCA)

PROGRAMFINAL

MAIN SPONSORS:

ORGANIZED BY: IN COLLABORATION WITH:

www.slca-sts.com

9CME HOURSACCREDITED FOR

www.slca-sts.comwww.slca-sts.com


It is my pleasure to announce the upcoming Thoracic Oncology Forum (TOF2015), the 3rd Annual Scientific Conference of the Saudi Lung Cancer Association (SLCA), which will take place in Crowne Plaza Hotel, Jeddah, Saudi Arabia on 09-11 April 2015.

Thoracic Oncology Forum (TOF) was first conducted in 2012 in conjunction with the GulfThoracic Congress in Dubai. It was founded with the objective of promoting the state of the art knowledge and expertise in the diagnosis and management of thoracic tumors to improve the clinical practice through high caliber scientific meeting, as well as promoting the exchange of knowledge amongst various professionals in the field.

The scientific committee aims is to provide an attractive scientific program with enhanced scientific and clinical sessions to explore the latest developments, medical advances, cutting edge diagnosis and breakthroughs in the management on all aspects of thoracic oncology.

At the TOF2015 a strong faculty of international, regional and local experts will be leading the pre-conference workshops as well as the main program. Abstracts posters and oral presentations will also be adopted during this meeting. In addition to TOF2015 is a platform to share updates, challenges and interesting findings in thoracic oncology.

All board members of the SLCA, TOF2015 Organizing Committee, warmly look forward to welcoming you and all your colleagues in Jeddah.

Thank you and best regards,

Prof. Abdul Rahman Jazieh, MD, MPH Chairman, Thoracic Oncology Forum (TOF2015)Chairman, Saudi Lung Cancer Association (SLCA)Chairman, Oncology DepartmentProfessor, King Saud bin Abdulaziz University for Health SciencesMinistry of National Guard- Health AffairsRiyadh, Saudi Arabia

2

CHAIRMAN’S MESSAGE


Jeddah is a city in the Hijaz Tihamah region on the coast of the Red Sea and is the major urban center of western Saudi Arabia. It is the largest city in Makkah Province, the largest sea port on the Red Sea, and the second-largest city in Saudi Arabia after the capital city, Riyadh. With a population currently at 5.1 million, Jeddah is an important commercial hub in Saudi Arabia.Jeddah is the principal gateway to Mecca, Islam’s holiest city, which able-bodied Muslims are required to visit at least once in their lifetime. It is also a gateway to Medina, the second holiest place in Islam.Economically, Jeddah is focusing on further developing capital investment in scientific and engineering leadership within Saudi Arabia, and the Middle East. Jeddah was independently ranked fourth in the Africa – Mid-East region in terms of innovation in 2009 in the Innovation Cities Index. Jeddah is one of Saudi Arabia’s primary resort cities and was named a Gamma world city by the Globalization and World Cities Study Group and Network (GaWC).Historically, Jeddah has been well known for its legendary money changers. The largest of said money changers at the time (the late Sheikh Salem Bin Mahfouz) eventually founded Saudi Arabia’s first bank, the National Commercial Bank (NCB).

ClimateJeddah features an arid climate under Koppen’s climate classification. Unlike other Saudi Arabian cities, Jeddah retains its warm temperature in winter, which can range from 15 °C (59 °F) at dawn to 28 °C (82 °F) in the afternoon. Summer temperatures are extremely hot, often breaking the 43 °C (109 °F) mark in the afternoon and dropping to 30 °C (86 °F) in the evening. Rainfall in Jeddah is generally sparse, and usually occurs in small amounts in November and December. Heavy thunderstorms are common in winter. The thunderstorm of December 2008 was the largest in recent memory, with rain reaching around 3 inches (7.6 cm). The lowest temperature ever recorded in Jeddah was 11.0 °C (51.8 °F) in March 1983. The highest temperature ever recorded in Jeddah was 49.0 °C (120.2 °F) on June 9, 1961. Dust storms happen in summer and sometimes in winter, coming from the Arabian Peninsula’s deserts or from North Africa.

EconomyJeddah has long been a port city. Even before being designated the port city for Mecca, Jeddah was a trading hub for the region. In the 19th century, goods such as mother-of-pearl, tortoise shells, frankincense, and spices

were routinely exported from the city. Apart from this, many imports into the city were destined for further transit to the Suez, Africa, or Europe. Many goods passing through Jeddah could not even be found in the city or even in Arabia.All of the capitals of the Middle East and North Africa are within two hours flying distance of Jeddah, making it the second commercial center of the Middle East after Dubai. Also, Jeddah’s industrial district is the fourth largest industrial city in Saudi Arabia after Riyadh, Jubail and Yanbu.

CultureReligious SignificanceMost citizens are Sunni Muslims. The government, courts and civil and criminal laws enforce a moral code established by Shari’ah. A very small minority of Saudi citizens is Shia Muslims, and there is also a large foreign workforce who is forbidden to follow their non-Islamic religions even privately, but this is little enforced.The city has over 1,300 mosques. The law does not allow other religions’ buildings, books, icons and expressions of faith. However, private religious observance not involving Muslims nor offending public order and morality is sometimes tolerated.Since the 7th century, Jeddah has hosted millions of Muslim pilgrims from all over the world on their way to Hajj. This merge with pilgrims has a major impact on the society, religion, and economy of Jeddah. It also brings an annual risk of illness, known by locals as the ‘hajji disease’, a general term for various viral maladies.

LandmarksKing Fahd’s FountainKing Fahd’s Fountain was built in the 1980s, can be seen from a great distance and, at 312 metres (1,024 ft), is the highest water jet in the world according to the Guinness World Records. The fountain was donated to the City of Jeddah by the late King Fahd bin Abdul Aziz, after whom it was named.Entrance of MakkahThe Makkah Gate, named the “Quran Gate”, is located on the Makkah Mukkarram road of the Jeddah-Makkah Highway. It is the entrance to Makkah and the birthplace of Muhammad. The gate signifies the boundary of the haram area of the city of Makkah, where non-Muslims are prohibited to enter.The gate was designed in 1979 by an Egyptian architect, Samir Elabd, for the architectural firm IDEA Center. The structure is that of a book, representing the Qur’an, sitting on a rehal, or book stand.

ABOUT JEDDAH

3


Badges: Name badges must be visible and used at all times, anywhere at the conference venue, and off- site social activities. Colors: Description: Green: Faculty (all access) Red: Delegate (all access, except speaker preview room) Purple: Exhibitor (no access to scientific sessions) Yellow: Staff

CME Certification: This Conference is accredited by The Saudi Commission for Health Specialties (SCFHS) for 9 hours for the main Conference. Certificates will be released onsite after filing the Conference evaluation forms.

Conference Bags: Conference bags will be distributed to registered participants at the Registration Desk.

Faculty Check in: There is a dedicated faculty lounge & preview room for faculty’s registration and badge collection and is operational at the same time as the registration desks.

Food & Beverage: Coffee breaks and lunch will be open to registered delegates. The hotel also offers a variety of all day dining restaurants to choose from. Anybody with Conference badge are eligible to go the designated restaurants within the hotel.

Automated Teller Machines (ATM): There is an ATM located in the Hotel Lobby

Rules: Smoking Policy in the Hotel: The entire hotel is non smoking. Mobile Phones- Delegates are kindly requested to keep their mobile phones in the off mode in meeting rooms when scientific sessions are in progress.

Parking: 24 hours valet parking is available at the Conference venue.

Prayer Room:Prayer rooms are available in the Event Centre.

Faculty Lounge & Preview Room: All speakers are requested to report to the Faculty Lounge & Preview Room at least one hour before their lecture, for a final check on presentation material. The Faculty Lounge & Preview Room is available for speaker’s convenience throughout the Conference for final run-throughs of their presentations.

Evacuation Assembly Point: In case of an emergency evacuation procedure please proceed in an orderly fashion to the open area in front of the Events Centre. Please follow the instructions of the Hotel Staff Wardens at all times.

GENERAL INFORMATION

4

www.slca-sts.com

Conference ChairmanProf. Abdul Rahman Jazieh, MD, MPH Riyadh, Saudi Arabia

MemberProf. Fouad Al Dayel, MD, FRCPA, FRCPathRiyadh, Saudi Arabia

MemberProf. Medhat FarisRiyadh, Saudi Arabia

MemberSarah Al Ghanem, MD Riyadh, Saudi Arabia

MemberAdnan Saleh Al Hebshi, MD, FRCR(UK), FRCP(C), ABRJeddah, Saudi Arabia

MemberHamed Al Hussaini, MDRiyadh, Saudi Arabia

MemberHamdan Al Jahdali, MD, FRCPC,FCCPRiyadh, Saudi Arabia

MemberProf. Khaled M. Al Kattan, MD, FRCSRiyadh, Saudi Arabia

MemberKhalid Saleh, MDRiyadh, Saudi Arabia

MemberAshwaq Al Olayan, MD Riyadh, Saudi Arabia

MemberAmeen Al Omair, MD, FRCPC Riyadh, Saudi Arabia

MemberAbdullah Altwairqi, MD Riyadh, Saudi Arabia

Co-ChairmanTurki M. Al-Fayea, MD, ABIM, FRCPC Jeddah, Saudi Arabia

Executive DirectorHassan S. Alorainy BsRC, RRT, FAARCRiyadh, Saudi Arabia

ORGANIZING COMMITTEE

www.slca-sts.com

SCIENTIFIC COMMITTEE

MemberIbraheem S. Alomary, MD, FRCPCRiyadh, Saudi Arabia

MemberDr. JamalEldeen ZekriJeddah, Saudi Arabia

MemberAyman Al-Sulaimani, MBBS, FRCSC, MHSc FRCPCJeddah, Saudi Arabia

MemberDr. Hatim Q. Al-Maghraby, MD, FRCP (Canada)Jeddah, Saudi Arabia

Conference ChairmanProf. Abdul Rahman Jazieh, MD, MPH Riyadh, Saudi Arabia

Co-ChairmanTurki M. Al-Fayea, MD, ABIM, FRCPC Jeddah, Saudi Arabia

Executive DirectorHassan S. Alorainy BsRC, RRT, FAARCRiyadh, Saudi Arabia

10

Guidelines Adaptation Training Workshop

PROGRAM DIRECTOR: PROF. ABDUL RAHMAn JAZIEH (KSA)

PRE-CONFERENCE WORKSHOPS & COURSES

CONDUCTED by:

Introduction:

In this workshop, participants will learn about clinical practice guidelines especially NCCN guidelines adaptation, development and update. Participants will also practice this guideline in their Institution.

Target Audience:

All Healthcare Professionals interested in Oncology.

Objectives:

• To learn about the process of development and update of NCCN guidelines.• To learn and practice about the adaptation of NCCN guidelines to the local setting.

THURSDAY, 9 APRIL 2015 13:00 - 17:00 MEETING ROOM: 8

www.slca-sts.com

Guidelines Adaptation Training Workshop


Time Topic SpeAKeR

12:30 – 13:00 Registration

13:00 – 13:30 Overview of Clinical Practice Guidelines Dr. Abdul Rahman Jazieh - KSA

13:30 – 14:00 The Process of Developing NCCN Guideline Dr. David Ettinger - USA

14:00 – 14:30 NCCN Guideline Adaptation Process Dr. Abdul Rahman Jazieh - KSA

14:30 – 15:00 COFFEE BREAK

15:00 – 15:30 How to Search for the Evidence TBA

15:30 – 16:30 Practice: Adaptation of Guidelines to the Institution Dr. Abdul Rahman Jazieh - KSA

16:30 – 17:00 MENA NCCN Coordinating Center Dr. Ashwaq Al Olayan - KSA

17:00 Adjourn

14

Prof. Abdul Rahman Jazieh, MD, MPH Chairman, Thoracic Oncology Forum (TOF2015)Chairman, Saudi Lung Cancer Association (SLCA)Chairman, Oncology Department, Professor, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard- Health AffairsRiyadh, Saudi Arabia

Prof. David S. Ettinger, MD Professor of OncologyProfessor of Gynecology and ObstetricsProfessor of MedicineProfessor of Otolaryngology-Head and Neck SurgeryProfessor of Radiation Oncology and Molecular Radiation SciencesJohns Hopkins MedicineBaltimore, MD, USA

Ashwaq Al Olayan, MDDirector, MENA NCCN Coordinating Centerand Consultant, Adult Medical Oncology,Department of Oncology ,King Abdulaziz Medical CityRiyadh, Saudi Arabia

Anaplastic Lymphoma Kinase (ALK) Testing Workshop

Introduction:

Lung Cancer is one of the most common cancers worldwide. Translocation in the anaplastic lymphoma kinase (ALK) gene discovered in 2007 is considered an important oncogenic driver in lung adenocarcinoma. Testing for mutation in this gene by fluorescence in-situ hybridization (FISH) technique is recommended.

Target Audience:

• Pathologists• Oncologists• Scientists• Trainees• Medical Technologists

Objectives:

The primary objective is to discuss the preanalytical, analytical and post analytical phases for ALK FISH testing. Also there will be overview of pathology of lung adenocarcinoma.

Summary:

The workshop will review the ALK molecular testing guidelines and applications as proposed by College of American Pathologists, International Association for Study of Lung Cancer and Association for Molecular Pathology.

PROGRAM DIRECTOR: PROF. FOUAD AL DAyEL (KSA)


CONDUCTED by:

THURSDAY, 9 APRIL 2015 13:00 - 17:00 MEETING ROOM: 9

www.slca-sts.com


Anaplastic Lymphoma Kinase (ALK) Testing Workshop

Prof. Abdul Rahman Jazieh, MD, MPH Chairman, Thoracic Oncology Forum (TOF2015)Chairman, Saudi Lung Cancer Association (SLCA)Chairman, Oncology Department, Professor, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard- Health AffairsRiyadh, Saudi Arabia

Hanaa S. Bamefleh, MBchB, FRCPC, MME, FIAC, CPHHA Deputy Chairmana, Lab EducationDepartment of Pathology and Laboratory MedicineKing Abdulaziz Medical CityRiyadh, Saudi Arabia

Shamayel Mohammed Consultant Pathologist, Section of Anatomic PathologyDepartment of Pathology and Laboratory MedicineKing Faisal Specialist Hospital and Research CentreRiyadh, Saudi Arabia

Prof. Fouad Al Dayel, MD, FRCPA, FRCPath Program Director Chairman, Department of Pathology and Laboratory MedicineKing Faisal Specialist Hospital & Research CentreRiyadh, Saudi Arabia

Prof. Walid E. Khalbuss, MD, PhD, FIACDirector GE Clarient LabratoriesRiyadh, Saudi Arabia

16

Time Topic SpeAKeR

12:30 - 12:50 Registration

12:50 - 13:00 Welcome and Introduction Dr. Abdul Rahman Jazieh - KSA

13:00 - 13:30 Tissue Sample, Handling and Processing Dr. Hanaa Bamefleh - KSA

13:30 - 14:00Overview of Pathological Classification of LungAdenocarcinoma

Dr. Walid Khalbuss - KSA

14:00 - 14:30 CAP Guidelines of ALK Testing Dr. Shamayel Mohammed - KSA

14:30 - 15:00 COFFEE BREAK

15:00 - 15:45 FISH Techniques TBA

15:45 - 16:30 Reporting of ALK Testing Dr. Fouad Al Dayel - KSA

16:30 - 17:00 Closing Remarks


SCIENTIFIC PROGRAMDAy 2 - FRIDAy, 10 ApRIL 2015Morning Session | 09:00 – 11:35

DAy 2 - FRIDAy, 10 ApRIL 2015Afternoon Session | 14:00 – 15:00

08:00 – 09:00 Registration

09:00 – 09:15 Opening and Welcome NotesProf. Abdul Rahman Jazieh Dr. Turki Al Fayae

Session 1

Moderators: Dr. Ameen Al Omair | Dr. Hanaa Bamefleh

09:15 – 09:35 Lung Cancer Screening Dr. Samira Alturkistany

09:35 – 09:55 How to Obtain Tissue Diagnosis Dr. Azzam Khankan

09:55 – 10:15 Role of Pathologist in Management of Lung Cancer Dr. Hatim Al Maghraby

10:15 – 10:35 BREAK

Session 2

Moderators: Dr. Hamdan Al Jahdali | Dr. Ibraheem Al Omary

10:35 – 10:55 Interventional Pulmonary Medicine: An Evolving Discipline Dr. Ahmed Aljohaney

10:55 – 11:15 Management of Early Non-Operable Lung Cancer Dr. Adnan Al Hebshi

11:15 – 11:35 Q & A

11:35 – 14:00 JuMAH PRAyER AND LuNCH

Session 3

Moderators Prof. Khaled Al Kattan Speakers Panelists

14:00 – 15:00

Multidisciplinary Interactive Session -1(Case 1)

Dr. Hamed Al-Hussaini (KFSH&RC- Riyadh) • Ahmed Bamousa (Surgery)

• Hatim Maghraby (Pathology)• Abdullah Al-Twairgi (M. Oncology)• Samira AlTurkistany (Radiology)• Ibraheem Al-Omary (R. Oncology)


Dr. Ashraf Aly (KFMC-Riyadh)

17


SCIENTIFIC PROGRAMDAy 3 - SATURDAy, 11 ApRIL 2015Morning Session | 08:30 – 12:30

Session 4

Moderators: Dr. Ashwaq Al Olayan | Dr. Hamed AlHusaini

08:40 – 09:00 Immunotherapy in Lung Cancer Dr. David Ettinger

09:00 – 09:20 Alignment of Lung Cancer Histology and Molecular Drivers Dr. Federico Cappuzzo

09:20 – 09:40EGFR TKI with Chemotherapy; Combined vs. Sequential in EGFR Mutant Cancer

Dr. David Ettinger

09:40 – 10:00What is the Optimal Second line Therapy in Driver Mutated Lung Cancer EGFR, ALK)

Dr. Federico Cappuzzo

10:00 – 10:20 BREAK

Session 5

Moderators: Prof. Medhat Faris | Dr. Muneera Al-Majed

10:20 – 10:40 Adaptation of NCCN Guidelines Prof. Abdul Rahman Jazieh

10:40 – 11:00 Optimal Treatment for patients with ALK+ NSCLC Dr. Abdullah Al Twairgi

11:00 – 11:20Treatment of Metastatic Cancer without Driver Mutation, What’s New?

Dr. Federico Cappuzzo

11:20 – 11:40 Management of Oligo-Progression in Driver Mutated Lung Cancer Dr. Hamed AlHusaini

11:40 – 12:30 ABSTRACT PRESENTATIONS

11:50Small Cell Lung Cancer ( SCLC) in Never Smokers And Response To Oral Tyrosine Kinase Inhibitors (TKI): Case Report

Ashraf Elyamany Metwally - KFMC (Riyadh)

12:10TTF1 expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome

Shereef Elsamany - KAMC (Makkah)

12:30 CRP Evaluation in Non-Small Cell Lung Cancer Sherif Refaat Alsayed - New Clinic (Jeddah)

12:30 – 13:30 LuNCH AND POSTER vIEWING

DAy 3 - SATURDAy, 11 ApRIL 2015Afternoon Session | 13:30 – 15:00

Session 6

Moderators: Prof. Abdul Rahman Jazieh Speakers Panelists

13:30 – 15:00


Dr. Nafisa Abdelhafiz (NGHA-Riyadh)

• Ayman Sulaimani (Surgery)• Hanna Bamefleh (Pathology)• Samira AlTurkistany (Radiology)• Hamed AlHussaini (M. Oncology)• Adnan AlHebshi (R. Oncology)Multidisciplinary Interactive Session -2

(Case 2)

Dr. Zuhair Al-Zubair (NGHA-Jeddah)

18

Federico Cappuzzo, MDDivision of Medical OncologyBellaria HospitalMilan, Italy

Dr. Federico Cappuzzo has been the Director of Medical Oncology Department at the Istituto Toscano Tumori-Ospedale Civile-Livorno since January 2010. In November 1992, he graduated, summa cum laude, in Medicine and surgery at the Palermo University and in November 1996, yielded a Degree summa cum laude in Medical Oncology at Milan University, followed by the ESMO (European Society for Medical Oncology) certification in Medical Oncology in 1997.

From 1997 to 1999 he was recipient of an ESMO Fellowship on Gene Therapy of Lung Cancer at Institut Gustave Roussy in Villejuif (Paris). Followed by attendance from April 2000 to September 2000 at the thoracic oncology unit at Medical University of South Carolina in Charleston (USA). For six years, from November 2000 to 2006, he was assistant professor at Ospedale Bellaria in Bologna and from November 2006 to January 2010 he was assistant professor in Medical Oncology at Istituto Clinico Humanitas IRCCS in Rozzano (Milano), which was followed in January 2004 to November 2004 as visiting associate professor in Medical Oncology at University of Colorado in Denver (USA).

Dr. Cappuzzo is a member of the Italian Association in Medical Oncology (AIOM), European Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Member of the editorial board of Lung Cancer. In 2006 and 2009 he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 150 papers in peer-review journals, mainly in translational research in lung cancer.

FACULTY - PROFILEHanaa S. Bamefleh, MBchB, FRCPC, MME, FIAC, CPHHADeputy Chairmana, Lab EducationDepartment of Pathology and Laboratory MedicineKing Abdulaziz Medical CityRiyadh, Saudi Arabia

•Consultant of Anatomic Pathology and Pulmonary Pathology, KING ABDULAZIZ MEDICAL CITY (KAMC), Riyadh, Saudi Arabia

•Assistant Professor KING SAUD BIN ABDULAZIZ UNIVERSITY for HAELTH SCIENCES (KSAU-HS)•Canadian Board of Anatomic Pathology, McGill University, Montreal, Quebec, Canada. 1992•Fellowship in Pulmonary Pathology & Cytopathology, McGill University, Montreal, Quebec, Canada. 1993•Fellow of the International Academy of Cytopathology, (FIAC). 2009•Master in Medical Education from KSAU-HS (MME). 2011•Deputy Chairman for Education Department of Pathology and Laboratory Medicine (DPLM), KAMC. 2011-current•Founder of Saudi Board of Anatomic Pathology, Saudi Commission for Health specialties (SCFHS). Since 2007

Bristol-Myers Squibb is a global BioPharma company firmly focused on its Mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B, HIV/AIDS, rheumatoid arthritis and psychiatric disorders.

At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

www.slca-sts.com

FACULTY - PROFILEProf. Fouad Al Dayel, MD, FRCPA, FRCPath Chairman, Department of Pathology and Laboratory MedicineKing Faisal Specialist Hospital & Research CentreRiyadh, Saudi Arabia

Chairman Department of Pathology and Laboratory Medicine King Faisal Specialist Hospital and Research Centre Riyadh, Saudi Arabia

professor of pathology College of Medicine, Al Faisal University Riyadh, Saudi Arabia

International Fellow College of American Pathologists

Corresponding Fellow for Saudi Arabia Royal College of Pathologists of Australasia

Deputy CAp Commissioner for Middle East College of American Pathologists Northfield IL, USA

OTHER TITLES: Consultant Anatomic Pathologist (1995 to present) Department of Pathology and Laboratory Medicine King Faisal Specialist Hospital and Research Centre

SUBSpECIALTy INTERESTS: Lung Pathology Bone Pathology Diagnostic Molecular Oncology of solid tumors Stem Cell Applications in Clinical and Research (Cell Therapy) Laboratory Accreditation and Quality Management Total Lab Automation Cancer Genomic Research (ICGC Project) NO. OF pUBLICATIONS: 122 NO. OF ABSTRACTS: 152

Prof. David S. Ettinger, MDProfessor of OncologyProfessor of Gynecology and ObstetricsProfessor of MedicineProfessor of Otolaryngology-Head and Neck SurgeryProfessor of Radiation Oncology and Molecular Radiation SciencesJohns Hopkins MedicineBaltimore, MD, USA

David S. Ettinger, MD, is the Alex Grass Professor of Oncology at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He is also a professor of medicine, otolaryngology, head and neck surgery, gynecology and obstetrics, and radiation oncology and molecular radiation sciences.

Dr. Ettinger received his medical degree from the University of Louisville, School of Medicine. He completed his medical internship and residency at the Albany Medical Center and Mayo Clinic, respectively. Dr. Ettinger completed his training in medical oncology at Johns Hopkins in 1975, and since then has been on the faculty of the School of Medicine.

20

FACULTY - PROFILE

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com

He was chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group (1980 to1982) and from 1990-2010, he was chairman of the Medical Oncology Lung Subcommittee of the Radiation Therapy Oncology Group.

Dr. Ettinger is a member of the board of directors of the National Comprehensive Cancer Network (NCCN) as well as a member of the NCCN Guidelines Steering Committee. In addition, he has been chairman of the NCCN non–small cell lung cancer practice guidelines panel, antiemetic practice guidelines panel, and occult primary tumor practice guidelines panel From 1982 through 1990, he was principal investigator of the phase I studies of new anticancer agents, sponsored by the National Institutes of Health.

Dr. Ettinger’s research interests are in new drug development and innovative multidisciplinary treatment strategies in lung cancer and sarcomas. He is also interested in improving supportive care measures associated with cancer and its treatment.

Dr. Ettinger has authored or co-authored over 200 articles and serves as an editor for Current Treatment Options in Oncology. He has edited 3 books: Thoracic Oncology, Kluwer Academic Publishers, 2001; Current Cancer Therapeutics, 5th Edition, Springer, 2009; and Supportive Care in Cancer Therapy, Humana Press, 2009. Dr. Ettinger is a former president of the Maryland Division of the American Cancer Society. In 1997, he received the American Cancer Society’s highest national divisional award, the St. George Medal. Dr. Ettinger has experience in oncology internationally both through Johns Hopkins international (JHI) and NCCN. He is the Associate Medical Director for Johns Hopkins Singapore since 2000.

He was involved in the development of oncology for JHI at the Tawam Hospital in Al Ain, UAE. In addition, Dr. Ettinger has been to Qatar, Saudi Arabia and India for JHI assessing oncology programs there.

He has presented the NSCLC Guidelines in China, the Middle East and Brazil for the NCCN as well as assessing research opportunities in China.

He is the Medical Director of the Johns Hopkins Home Care Group and serves on a number of committees both in the Kimmel Cancer Center including its Promotions Committee and in the Johns Hopkins Hospital including the Risk Management Committee and Credentials Committee.

FACULTY - PROFILETurki M. Al-FayaeConsultant Medical OncologistAssistant Professor, KSAU-HSPrincess Noorah Oncology CentreKing Abdulaziz Medical CityJeddah, Saudi Arabia

Consultant Internal Medicine & Thoracic Oncology: Princess Noora Oncology Center, King Abdulaziz Medical City/National Guard Health Affairs, Jeddah- Saudi Arabia (July 2010- present).

Fellowship program Director, Adult Medical Oncology: Princess Noora Oncology Center, King Abdulaziz Medical City/National Guard Health Affairs, Jeddah- Saudi Arabia

Assistant professor / Internal Medicine & Oncology: King Saud Bin Abdulaziz University for Health Science (KSAU-HS), Jeddah- Saudi Arabia

Red Sea Lung Cancer Group (ReSLunG): Co-Leader: nonprofit organization aimed to increase the awareness of lung cancer and its diagnosis and treatment among medical society (January 2013 - Present)

Regional Advisory Member in many Boards in the field of Lung Cancer: Kingdom of Saudi Arabia and gulf States Countries.

Certifications:• American Board Diplomate of Medical Oncology: (November, 2009)• Fellowship of the Royal College of Physicians & Surgeons of Canada in Medical Oncology (FRCPC): (September,

2009)• Fellowship of the Royal College of Physicians & Surgeons of Canada in Internal Medicine (FRCPC): (May, 2008)• American Board Diplomate of Internal Medicine (ABIM): (August, 2007)• Diplomate in Military Medical Field: (April, 2001)• MBBS (MD equivalent): Medical School of King Faisal University. Dammam - Saudi Arabia (1994-1999)

1www.slca-sts.com

Hamed AlHusaini, MDConsultant, Medical OncologyAssistant Professor, Al Faisal UniversityKing Faisal Cancer CenterKing Faisal Specialist Hospital and Research CenterRiyadh, Saudi Arabia

Fellowship training:Two years of Medical Oncology fellowship training at King Faisal Specialist Hospital (from May 2004 to May 2006)Clinical fellowship of Medical Oncology at Princess Margaret Hospital for two years (from July 2006 to June 2008)

Those include: breast cancer, lung cancer, lymphoma & autologus bone marrow transplant, gastrointestinal cancer, genitourinary cancer, CNS tumor, head &neck cancer, Gyneoncology, sarcoma. In addition to that I did two month in malignant hematology, one month in radiation oncology and one month in pathology.

publication:A. Had written 20 ManuscriptsB. Abstracts

22

FACULTY - PROFILE• EGFR Mutation Testing in Saudi Arabian Lung Adenocarcinoma. Fouad ALdayel, Hamed ALHusaini, Hala Abalkhail.

Poster presentation at 15th world Conference on Lung cancer, Sydney, Australia. 27-30 Oct 2013, P3.18-008• Frequency of ALK gene rearrangement in Saudi lung cancer. Fouad ALdayel, Hamed Alhusaini, Khawla alkuraya

Poster presentation at 15th world Conference on Lung cancer, Sydney, Australia. 27-30 Oct 2013, P2.02-010• Bone Marrow Sparing Image Guided Intensity Modulated Radiotherapy with Simultaneous Integrated Boost (SIB) in

Locally Advanced Cervix Cancer. M Hegazy, Rana Mahmood, Hamed ALHusaini, Belal Moftah. ICRM2014, Abstract NO:0090

• Hemosidren Endocrinopathy IN Patients with B Thalassimia. AT 83 ANNUAL MEETING ENDOCRINE SOCIETY USA CHLORADO JUNE 2001 AND IN RESEARCH PROMOTION DAY, KFSH MAY 2001. ALHusaini H, Mohammed A.

Ongoing Research:• A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced

Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial. RAC# 2131 039 • Identification of the Mutational Spectrum and Frequencies of BRCA1 & BRCA 2 Genes in Saudi Breast and Ovarian

Cancer Populations. RAC#2130037• Retrospective epidemiology study of ALK rearrangement in non-small lung cancer patients in the Middle East and

North Africa. RAC#2141137• The study of Druggable Molecular abnormalities in Non Squamous non-small cell lung cancer in Middle East.

RAC#2141010• Single institutional experience of ovarian granulosa cell tumor.

Adnan Saleh Al Hebshi, MD, FRCR(UK), FRCP(C), ABRConsultant, Radiation Oncology at KFSH & RC Member, IMRT (Intensity Modulated Radiation Therapy)Head of the StereotacticRadiosurgery (SRS),and StereotacticRadiotherapy (SRT) program,Teaching and LecturingRiyadh, Saudi Arabia

Education / QualificationMay 2006 - FRCp (C) - Fellowship of Royal College of Physician and Surgeon of CanadaMay 2005 - ABR - The American Board of Radiology Radiation OncologyMay 2001 - FRCR(UK) - Fellowship of The Royal College of Radiologists (Clinical Oncology) London – UKJune 1990 - MBBS - King AbdulAziz University Medical College and Allied Science Jeddah - KSA

Current post: Consultant and Head section Of Radiation Oncology Jeddah -KFSHRC

Other Duties:• President of the Saudi Oncology Society (SOS)• Assistant Professor – Alfaisal University• Member of the Gulf Cancer Care and Protection Board• Member of the stereotactic Radiosurgery Society (SRS)• Member of ASTRO the American Society of Therapeutic Radiation Oncology

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.

Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.

www.slca-sts.com

FACULTY - PROFILEProf. Abdul Rahman Jazieh, MD, MPH Chairman, Thoracic Oncology Forum (TOF2015)Chairman, Saudi Lung Cancer Association (SLCA)Chairman, Oncology DepartmentProfessor, King Saud bin Abdulaziz University for Health SciencesMinistry of National Guard- Health AffairsRiyadh, Saudi Arabia

Current positions: Chairman, Department of Oncology, KAMC, Riyadh, KSA01/2006- Present: Professor, King Saud bin Abdulaziz University for Health Sciences06/2011- Present: Member, ASCO International Affairs Committee

Medical Education:MD Sept, 1988 Damascus University Medical School, SyriaMPH May 1997 Master’s Degree in Public Health from Tulane, University, New Orleans, and Major in Health Education/Communication

Residency:7/90 – 6/93 Internal Medicine Residency at St. Francis Hospital, an affiliate of U of Illinois, Evanston, Illinois

Fellowship:7/93 – 6/ 96Hematology and Medical Oncology Fellowship, University of Arkansas for Medical Sciences, Little Rock, Arkansas

previous Appointments:• 7/96 - 6/00 Assistant Professor of Medicine, Division of Hematology/Oncology University of Arkansas for Medical

Sciences (UAMS), Little Rock, Arkansas.• 7/00 – 8/04 Associate Professor of Medicine, Division of Hematology/Medical Oncology at University of Cincinnati

(UC), Cincinnati, Ohio.• 9/04 – 1/06 Professor of Medicine, Division of Hematology/Medical Oncology at University of Cincinnati (UC),

Cincinnati, Ohio• 5/02 – 1/06 Directors, Division of Hematology/Medical Oncology University of Cincinnati Medical Center, Cincinnati,

Ohio

Board Certifications:Internal Medicine Board, Hematology Board and Medical Oncology Board, USA

Licensure:Licensed to practice Medicine in OHIO, USA and Saudi Arabia

Memberships:Fellow American College of Physicians (FACP), American Society of Hematology, American Society of Clinical Oncology, American Medical Association, American Association for Cancer Research, American Association of Cancer Education

Awards and Honors:1982 Merit Award Recipient from the Syrian Ministry of Education. 1995 Merit Award Recipient from the American Society of Clinical Oncology. 2004 “40 under 40” People to Watch at the UC Medical Center 2005 “Unsung Hero Award” by Cancer Family Care, Cincinnati, OH2006 Proclamation to the City of Cincinnati naming the day of January 5th 2006 as Dr. Abdul Rahman Jazieh day

publications:Dr. Abdulrahman Jazieh has more than 100 publications as manuscripts, book chapters and abstracts.

24

www.slca-sts.com

FACULTY - PROFILEAhmed Abdulaziz Aljohaney, MBBS, DABIM, FRCPCAssistant Professor of MedicineCollege of Medicine, King Abdulaziz UniversityConsultant in Pulmonary Medicine and Interventional PulmonologyKing Abdulaziz University HospitalSecretary General of Saudi Society of Internal Medicine (SSIM) Riyadh, Saudi Arabia

Dr Ahmed Aljohaney is an Assistant Professor of Medicine and Consultant Interventional Pulmonologist at King abdulaziz University Hospital and Faculty of Medicine.

Dr Aljohaney received his medical degree with honor at King Abdulaziz University. Dr Aljohaney Completed a residency in Internal medicine and fellowship training in Pulmonary and Interventional Pulmonology at University of Ottawa, Ontario, Canada 2005-2011.

He is certified by the Royal College of physicians and surgeons of Canada and the American board of internal medicine in the field of internal medicine and pulmonary medicine. He is proud to be the first Saudi Doctor specialized in Interventional Pulmonology.

He has an advanced training in the field of bronchoscopy and pleural diseases. His clinical and research interest involve diagnosis and staging of lung cancer and pleural diseases as well as procedural training , simulation and medical education.

He is currently the secretary general for the Saudi society of internal medicine and a fellow of the American college of chest physicians. MD, MS

Walid E. Khalbus, MD, PHD, FIACProfessor of Pathology University of Pittsburgh, Pittsburgh, PA, USA Medical Director of GE Clarinet Diagnostic Services and Cytology NGHA Hospital-RiyadhRiyadh, Saudi Arabia

Dr. Walid E. Khalbuss is a professor of pathology at University, of Pittsburgh, Pittsburgh, Pennsylvania, USA. He is also the Medical Director of GE Clarient Diagnostic Services at National Guard Hospital (NGHA)-Riyadh, KSA. Dr. Khalbuss has board certifications in Anatomic Pathology; Clinical Pathology, and Cytopathology from the American Board of Pathology. He did his pathology training including two fellowships: one in Oncologic Surgical Pathology and one in Clinical Cytopathology at the New York Medical College, Valhalla, New York, USA. His pathology training and fellowship were under supervision of Dr. Myron M. Melamed; a known pioneer pathologist and ex-chairman of Pathology Department at Sloan Kettering Memorial hospital, New York, NY.

Dr. Khalbuss has published extensively, and has been a speaker in major pathology meetings such as CAP; USCAP; ASCP, ASC; BSCC; and IAC. He has to his credit 89 peer-reviewed articles in major scientific journals, over 134 abstracts; 7 textbooks and Atlases in pathology, and numerous book chapters. He travels widely and is a sought after speaker nationally and internationally.

He is a member of the College of American Pathologists (CAP); American Society of Clinical Pathology (ASCP); and a member of the International Academy of Cytology (IAC) Educational and QA Committee. He is on the editorial board of several journals and has major appointments in several professional Pathology organizations. His major areas of interest include pathology informatics; QA, ancillary testing, FNA cytology, and EBUS cytopathology.

25

FACULTY - PROFILEAzzam Khankan, MDConsultant Interventional RadiologistDepartment of Medical ImagingKing Abdulaziz Medical CityRiyadh, Saudi Arabia

Azzam Khankan, MD, PhD is a consultant interventional radiologist at King Abdulaziz Medical City (National Guard Hospital) in Riyadh, Saudi Arabia.

Dr. Khankan received both undergraduate medical education and radiology residency training at Damascus University and its hospitals in Syria. Subsequently, he pursued a postgraduate education and advanced clinical training in interventional radiology at Osaka University and its hospital in Osaka, Japan where he earned his Degree of Philosophy in Medical Sciences.

He served as a research fellow at the National Cardiovascular Center in Osaka, Japan where he worked dedicatedly in biomedical research. Then, he completed additional fellowship training in interventional radiology at McGill University Health Center, Montreal, Canada and in pediatric interventional radiology at the Hospital for Sick Children, Toronto, Canada.

Dr. Khankan is active in multiple aspects of interventional radiology and has been performing a wide variety of vascular and non-vascular interventions.

He has a special interest in interventional oncology (hepatobiliary and lung) and embolotherapy. He is the author of numerous published abstracts and many peer-reviewed journal articles and he participated actively in the conferences of top European and American radiologic societies.

MSD also known as Merck Sharp & Dohme (in the US: Merck & Co., Inc., Whitehouse Station, N.J.) is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, MSD discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Merck Sharp & Dohme (MSD) has been present for more than 35 years in the Gulf region.MSD Gulf operates throughout offices based in the capitals of UAE, Kuwait, Bahrain, Qatar & Oman and ranks amongst the leading pharmaceutical companies throughout the Gulf region.

Through its local distributors, MSD Gulf provides innovative medications in several disease entities. These include products for Cardiovascular, Asthma, Pain & inflammation, Osteoporosis, Neurological, and ophthalmic pathological disorders, in addition to several specialized Hospital products and Vaccines.

Contact Person: Emad El Swerky

Address: Dhcc, Al Faris Building #39 Dubai | United Arab Emirates

Postcode: PO Box 2096 | Dubai | United Arab EmiratesTelephone: +971.4.44269100Fax: +971.4.44269205

Email: [email protected]: msd.com

Shamayel MohammedConsultant Pathologist, Section of Anatomic PathologyDepartment of Pathology and Laboratory MedicineKing Faisal Specialist Hospital and Research CentreRiyadh, Saudi Arabia

Education:• Obtained MBBS with Honors from King Saud University Medical School, Riyadh, Saudi Arabia• After finishing the King Saud Fellowship Residency training program in Anatomic Pathology, Dr.Shamayel obtained

her fellowships in Lymphoma Pathology and Cardio-Pulmonary Pathology from University of Alberta, Canada.

Current Position:• Consultant of Anatomic Pathology, Lymphoma Pathology and Pulmonary Pathology, Department of Pathology and

Laboratory Medicine, King Faisal Specialist Hospital and Research Center (KFSH&RC) , Riyadh, Saudi Arabia• Chairperson Scientific Committee, Saudi Board of Anatomic Pathology, Saudi Commission for Health Sciences

(SCFHS)

Membership:• Member of US-CAP• Member of Saudi Lung Cancer Association- Saudi Thoracic Society• Member of Saudi Society of Bone Marrow Transplantation• Member of Saudi Lymphoma Group• Member of Saudi Cancer Society• Children Oncology Group

Publication:• 11 publication• 4 abstracts• Two ongoing RAC approved research projects

Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas, including: Oncology, Hematology, HCV, HIV, Immunology, neuroscience in addition to other therapeutic areas.

Oncology and Hematology fields are considered as one of the main strongholds for Janssen with a wide variety of registered products like (Zytiga) for prostate cancer, (Yondlis) for Soft tissue sarcoma and recurrent ovarian cancer and (Velcade) for multiple myelomas in addition to other innovative medications in the pipelines or under local registration that fulfil some the current unmet medical needs in different disease areas.

Our ultimate goal is to help people live healthy lives. We have produced and marketed many first-in-class prescription medications and are poised to serve the broad needs of the healthcare market – from patients to practitioners, from clinics to hospitals.

(We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality….) our Credo

FACULTY - PROFILE

www.slca-sts.com

FACULTY - PROFILEDr. Hatim Q. Al-Maghraby, MD, FRCP (Canada)Assistant Professor at King Saud bin Abdulaziz University Residency Training Program DirectorConsultant Pathologist/CytopathologistDepartment of Pathology and Lab. MedicineKing Abdulaziz Medical City- Jeddah Jeddah, Saudi Arabia

biography:Dr. Hatim Al-Maghraby graduated in 2001 from King Abdulaziz University Medical School, Jeddah, Saudi Arabia. He did his Residency Training at The University of Ottawa, Ottawa, ON, Canada; and received his Fellowship of The Royal College of Physicians and Surgeons of Canada (FRCPSC) in 2008.

He did two years of fellowship training, that included Cytopathology, Liver and Medical Kidney Diseases at The University of Toronto, Toronto, ON, Canada. He started working at King Abdulaziz Medical City from 2010 until currently. He is also an Assistant Professor of Pathology at King Saud University for Health Sciences- Jeddah. He is actively involved in diagnosis/management of lung cancer patients at his institute and is a member of the lung cancer tumor board at his institute.

Dr. Al-Maghraby’s interests include: Molecular diagnosis of lung cancer and Cytopathology of the lung tumors.

Ashwaq Al Olayan, MDDirector, MENA NCCN Coordinating Centerand Consultant, Adult Medical Oncology,Department of Oncology ,King Abdulaziz Medical City Riyadh, Saudi Arabia

Summary of qualifications:2000 Bachelor Degree of Medicine and Surgery, King Saud University,Faculty of Medicine, Riyadh, Saudi ArabiaDecember 2005 Saudi Board Internal Medicine November 2006 Arab Board in Internal Medicine

Work experience:Oct 2001- Sept 2004: Resident internal Medicine.Oct 2005 -Feb 2006: Senior Staff (board eligible) in Internal Medicine.Mar 2006 - Jun 2007 : Oncology Fellow in Cancer Center King Fahad National Guard Hospital.Jul 2007 -Jun 2009 : Medical Oncology Fellowship Training in McMaster University (Canada)

Achievements:Reviewing and creating guideline in all site for oncology in centerMember of thoracic and Gastroenterology group in setting national guidelineCo-Charmin in patient education committeeCo-Charm in in Gastrointestinal tumor board

publications:Successful Management of Massive Subcutaneous Emphysema with Subcutaneously - Inserted Angiocatheters . Case report and review of the literature.Tuberculosis in ICU

28

FACULTY - PROFILE

Abdullah K. Altwairgi, MDConsultant, Adult Medical OncologyKing Fahad Medical CityRiyadh, Saudi Arabia

Dr. Abdullah Altwairgi is a Consultant Medical Oncologist at Comprehensive Cancer Center, King Fahad Medical city in Riyadh. His current practice involves treatment of patients with Breast, lung and CNS cancers.

Dr Altwairgi graduated from Medical College, King Abdulaziz University, and trained in internal medicine at Security Forces Hospital in Riyadh. He obtained a Fellowship in Medical Oncology and undertook a clinical fellowship in Breast and Lung Oncology at Queen’s University, Canada from 2008–2011. He was appointed as a Consultant Medical Oncologist at King Fahad Medical city in October 2012.

Dr Altwairgi is actively involved in clinical trials and clinical research. He undertook a clinical trials Methodology fellowship at NCIC Clinical Trials Group in 2012. He has given local and international presentations and was awarded the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award for his research in 2012. Other prizes include the First Place (Best Abstract), and Second Place Awards of Canadian Association of Medical Oncologists Annual Meeting in 2012. He has peer review publications in Journal of Clinical Oncology and other leading oncology journals.

Guideline management of small cell lung cancer. Guideline management of malignant mesothelimoa.Guideline management of Thymoma.Systematic therapy in NSCLC. Research projects:Retrospective review of triple negative breast Cancer Treated with Cisplatin and Etoposide in Juravinski Cancer Center.

Ongoing projects:Customization of Chemotherapy in lung cancer Erlotnib in Lung CancerOxaliplatin,Gemcitbine and Erlotinib study in patients with advance Chemo-na’lve Pancreatic cancer

Awards:Best Resident Internal Medicine 2004Best paper Award 2001-2002Second best paper award 2002-2000

Pfizer strives to translate the latest breakthroughs in cancer research into medicines that significantly impact the lives of cancer patients. Our research team uses a multi-disciplinary approach to identify and target specific alterations that drive the growth and progression of malignant disease. We combine innovative approaches to drug discovery with a strong emphasis on precision medicine, which matches targeted therapies with the patients most likely to respond to those therapies.

Our core research and development interests include cancer cell signaling mechanisms and oncogenic drivers, cancer stem cells, mechanisms of drug resistance, and technologies that enable selective drug delivery to tumor tissues. These foundational efforts are complemented by growing research interests in emerging areas of cancer biology including cancer metabolism and epigenetics. One key technology focus is advancing the next wave of ‘antibody drug conjugates’, which are targeted therapies that combine the specificity of an antibody with the cancer cell-killing power of chemotherapy.

FACULTY - PROFILESamira Alturkistany,MD,FRCPC,ABRConsultant Chest and Body ImagingResidency Program DirectorKing Faisal Specialist Hospital & Research Center-JeddahJeddah, Saudi Arabia

• Consultant Chest and Body Imaging and Residency program director• Finished residency at McGill university Montreal,Canada• Canadian and American boards certified• Chest and body imaging fellowships, Toronto university,Canada• Especial interst in Lung cancer screening and oncology imaging (Liver, Pancreas and Gynae)• Was involved as a fellow in the canadian lung cancer screening program Toronto.

DUBAI 2016

09 - 12 MARCH

Beyond Gulf Inspiration

www.gulfthoracic.com

www.slca-sts.com

Beyond Gulf Inspiration

TOF2015 - ABSTRACTSSmall Cell Lung Cancer ( SCLC) in Never Smokers And Response To Oral Tyrosine Kinase Inhibitors (TKI): Case Report

Ashraf Elyamany, Abdullah K. AlTwairgi, Medical Oncology Department, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia

Background: SCLC is a disseminated disease in most patients, even at presentation, almost occurs exclusively in smokers. Systemic chemotherapy remains the standard therapy in all patients. Despite that, the median survival for patients with extensive disease is 9 to 12 months. Mutations in the epidermal growth factor receptor gene (EGFR) typically found in minority of non–small-cell lung cancers (NSCLC), mainly adenocarcinomas, and often associated with the excellent response to EGFR tyrosine kinase inhibitors (TKI). However, majority of the data for screening of EGFR mutations in SCLC have been negative. Therefore, SCLC is not routinely tested for EGFR mutations worldwide, and the response to TKI in this histology subtype have not been systematically evaluated as well.Case description: A 73 years old gentlemen, never smoker and denied any history of environmental tobacco smoking , presented with 3 months history of shortness of breath, cough and left sided chest pain. He was diagnosed as SCLC based on trans-bronchial biopsy in August 2013. He was started on the first line Cisplatin/Etoposide chemotherapy (every 3 weeks regimen), with good initial clinical and radiological response after 3 cycles of the treatment. However, he developed significant disease progression shortly after completing the 6th cycle. Nevertheless, because of unusual negative smoking history, We requested EGFR mutation study on the initial specimen and exon 19 mutation was detected. Therefore, we have started him on TKI (Erlotinib) since 13 January 2014 with reasonable clinical and radiological response. Currently, he continues on Erlotinib, and remains clinically and radiologically stable till last follow up in 19 January 2015. Conclusion: Never smoker and presence of EGFR mutation is very uncommon findings in SCLC. Interestingly, TKI seems to be one of the novel treatment options that could impact the outcome of subset of SCLC patients who express mutated EGFR. The presence of EGFR mutation and response to TKI in SCLC patients should be further evaluated and warrant larger studies.

TTF1 expression in advanced non-small cell lung cancer: impact on survival outcome

ShereefElsamany, Turkey Al-fayea, Abdullah Alzahrani, Waleed Abozeed, WaseemDarwish, Mian Usman Farooq, Ahmed Madani, EsraaBukhari

Purpose: The prognostic role of TTF-1 expression in non-small cell lung cancer (NSCLC) was assessed in few studies with inconsistent results. The present study aims to evaluate the prognostic value of TTF1 expression in advanced non-squamous NSCLC.Methods: In this retrospective study, patients with stage IIIB-IV non-squamous NSCLC were included. Differences in progression free survival (PFS) and overall survival (OS) according to TTF1 expression status, type of 1st line chemotherapy (pemetrexed containing vs. others), EGFR status and other clinico-pathological parameters, were assessed using log rank test. Multivariate analyses using Cox proportional hazards models have been used to check for independent prognostic factors for PFS and OS.Results: One hundred and twenty patients with advanced non-squamous NSCLC were identified (stage IV: 100, stage IIIB: 20 and TTF1-positive: 100, TTF1-negative: 20). In univariate analysis, PFS was improved in patients with PS 0-2 (7.0 vs. 2.0 months, p= 0.002) and those who received pemetrexed-containing chemotherapy (9.2 vs. 5.8 months, p= 0.004). Meanwhile, PFS was improved in patients with TTF1-positive tumours; however, it did not reach statistical significance (6.8 months vs. 2.3 months, p= 0.17). OS was improved in female patients (23.0 vs. 8.7 months.

Innovation is an essence of Novartis MissionWhen science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patientslive with cancer and related diseases.At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients

patient-inspired solutions provide more than medicineTreating cancer and related diseases is about supporting patients with more than medicine:• Disease-specific programs provide comprehensive support to patients, helping to ensure the best outcome in collaboration with Health

Care Providers.• Our innovative portfolio of access-to-treatment projects adapts to patient needs, products, partners and countries• Novartis Oncology have 22 Medicines for 25 Oncological Conditions, with more than 25 Molecules & Targeting 19 Cancer Pathways.

www.slca-sts.com

TOF2015 - ABSTRACTSCase Series of Five Patients Experienced Cisplatin-related Thromboembolic Complications Including a Rare Event of Spinal Cord Ischemia in SCLC Patient.

Dr. Ersan Al- Zamel, MD, MSc. Registrar Clinical Oncology.

Background: It is a well-known that patients with advanced solid tumors receiving cisplatin-based chemotherapy are at significant risk of thromboembolism. During the last two years, Thromboembolic events during and shortly after cisplatin have been reported in two cases of SCLC, one case of breast cancer, and one case of metastatic nasopharyngeal carcinoma, and one case of testicular germ cell tumor. In this paper, we present a 67-year-old male, known to have well controlled hypertension and diabetes. Who was treated for extensive SCLC (liver, bone, bone marrow metastases) with six cycles of cisplatin and etopside followed by prophylactic cranial irradiation after achieving complete response. He presented with acute onset of quadriparesis, urine retention, constipation, and disorientation. MRI spine revealed diffuse intramedullar1y faint high signal intensity on T2 W1 without mass effects and some swelling in the cervico-dorsal area consistent with cord ischemia. He developed respiratory failure, intubated, and passed away few weeks later.Key words: Cord ischemia, thromboembolism, cisplatin, cancer.

CRP evaluation in non-small cell lung cancer

Sherif Alsyaed, Hassan Aref

Background: CRP is an inflammatory mediator that is shown to be elevated in different inflammatory and malignant conditions, the aim of the study to see whether the elevated serum CRP is correlated with the advanced stages and increased tumor size of NSCLC after exclusion of patients with high CRP due to infection. Materials and methods: 71 patients with proved NSCLC and 25 healthy control volunteers were selected for the study, serum CRP and PCT was analyzed, results of CRP in patients with NSCLC were compared with control group, and subgroups were made according to different clinical variables as subtypes of lung cancer, tumor staging and tumor size.Results: The serum CRP level was significantly higher in patients with NSCLC compared to control group 114.2±60.1 mg/ml vs. 13.4±8.6 mg/ml) with p value 0.05), no significant difference between NSCLC subtypes (p > 0.05), there was a positive correlation between CRP level and tumor size (p on is correlated with the tumor size and tumor staging but not to subtypes of NSCLC, it may point to poor outcome and poorer prognosis.

Malignant Pleural Effusion Biomarkers as Predictor for Chemical Pleurodesis Success

Sherif Alsayed, Samar Marzouk, Sherif Abelhalim and Essam Mousa

Background: Background: 42-77 % of exudative pleural effusions are due to malignant diseases (1) this study aimed to evaluate the value of biochemical parameters of the pleural aspirate in predicting success of chemical pleurodesis in adult patients with malignant pleural effusion.Patients and Methods: This prospective study included 30 adult patients with malignant pleural effusion diagnosed by clinical examination, Chest CT scanning and closed pleurocentesis. Patient ages mean of 60.4 ± 7.8 years, multiple sessions of closed pleurocentesis were carried out followed by insertion of an intercostal tube. The pleural aspirate was then sent for chemical analysis to detect Glucose, PH, and LDH. Pleurodesis was then done either by using Tetracycline (group A, or Bleomycin (group B). All patients were then followed up for success of the pleurodesis process within one month.Results: Within one month of follow-up, rates of clinical response to treatment in group A (Tetracycline) were successful in (40 %); versus group B (73.3 %). Complete response (CR) occurred in group A cases (20 %); versus (33.3 %) in group B; whereas partial response (PR) occurred in 3 cases of group A; versus 6 cases of group B; and treatment failure (TF) occurred in 9 of group A cases versus 4 of group B case. None of our patients died. Morbidity occurred in the form of mild-to-moderate. The success of the pleurodesis was closely-associated to a higher glucose and PH levels together with a low LDH level in the pleural fluid.Conclusion: The success rate of pleurodesis should be assessed in relation to biochemical parameters such as LDH in pleural fluid in addition to pH and glucose level as in patients with MPE, the success of pleurodesis is usually higher when the pleural fluid pH and glucose levels are high, and the LDH level is low, A low pH, and glucose level and a high LDH level is have a poorer outcome pleurodesis.Key-words: MPEs: Malignant Pleural Effusions

34

INDICATIONS: Malignant pleural mesothelioma, ALIMTA in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer, ALIMTA in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

ALIMTA is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic nonsmall cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

ALIMTA is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

DOSAGE AND ADMINISTRATION: Alimta is given as a 10min IV infusion in combination with cisplatin: Alimta 500 mg/m2 followed by cisplatin 75 mg/m2, both given day 1 of21 day cycle. Single agent use, ALIMTA 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.

Premedication Regimen: To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration. The corticosteroid should be equivalent to 4 mg of dexamethasone administered orally twice a day.To reduce toxicity, patients treated with pemetrexed must also receive vitamin supplementation.

Patients must take oral folic acid or a multivitamin containing folic acid (350 to 1000 micrograms) on a daily basis. At least five doses of folic acid must be taken during the seven days preceding the first dose of pemetrexed, and dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Patients must also receive an intramuscular injection of vitamin B12 (1000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed.

CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients, Breast-feeding Concomitant yellow fever vaccine.PRECAUTIONS: Patients receiving pemetrexed should be monitored before each dose with a complete blood count, including a differential white cell count (WCC) and platelet count.

Prior to each chemotherapy administration, blood chemistry tests should be collected to evaluate renal and hepatic function. Before the start of any cycle of chemotherapy, patients are required to have the following: absolute neutrophil count (ANC) should be ≥1500 cells/mm3 and platelets should be ≥100,000 cells/mm3. Creatinine clearance should be ≥45 ml/min.

The total bilirubin should be ≤1.5 times upper limit of normal. Alkaline phosphatase (AP), aspartate transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) should be ≤3 times upper limit of normal. Alkaline phosphatase, AST and ALT ≤5 times upper limit of normal is acceptable if liver has tumour involvement.

ADVERSE REACTIONS: The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.

Other undesirable effects include renal toxicities, increased transaminases, alopecia, fatigue, dehydration,rash, infection/sepsis and neuropathy. Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.

Our appreciatiOn gOes tO Our main spOnsOr�شكـــــــــر و تقدير

www.slca-sts.com37


www.slca-sts.com 38


www.slca-sts.com39


www.slca-sts.com 40

www.slca-sts.com

TOF2015Thoracic Oncology Forum

9-11 April 2015 | Crowne Plaza Hotel, Jeddah, Saudi Arabia

The 3rd Annual Scientific Conference of The Saudi Lung Cancer Association (SLCA)

P. O. Box 106911Riyadh 11676Saudi Arabia Telephone: (+966) 11 462 2515 Mobile: (+966) 53 390 0411E Mail: [email protected]

© Saudi Lung Cancer Association (SLCA)/ Saudi Thoracic Society 2015, All Rights Reserved

CONTACT:

view pamphlet

Documents